OSLO, NORWAY – 19 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) are happy to announce that Thailand Food and Drug Administration (“Thai FDA”) authority have granted GA license for the GA-map® Dysbiosis Test in Thailand. GA has, in cooperation with its distributor Hausen Bernstein Co. Ltd. (“HB”) filed for regulatory approval of the GA-map® Dysbiosis Test in 2022, and we are happy to announce that the test has now been approved by the Thai FDA authorities for Clinical use in IBS and IBD patients. HB plans to launch the GA-map from their molecular lab in Bangkok and market the GA-map® products in wider Thailand.
Ronny Hermansen, CEO, Genetic Analysis, comments:
“GA is proud to announce that Thai FDA authorities have approved the GA-map Dysbiosis Test. A regulatory approval will enable the doctor/specialist to use the Dysbiosis test for clinical diagnostic use in IBS and IBD patients. The GA-map® platform will enable Hausen Bernstein to supply the highest quality microbiome tests in Thailand”.
The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient’s microbiota. Together with HB, GA can now offer its Thai FDA-approved standardised gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis.
Dr. Banlang Luangwaranan, CEO, Hausen Bernstein, comments:
“HB are happy to announce that the GA-map Dysbiosis Test has received a Thai FDA license and that the GA-map Dysbiosis Test now will be available for clinical diagnostic use. We see that the focus on our Microbiome balance is rapidly increasing as people experience more and more gut-related problems. GA-map will be a great complement to our growing business of food allergy testing. The core value of HB is to offer the highest quality products to our customers, and we are proud to add GA-map to our portfolio of high-end products.”
For further information, please contact:
Ronny Hermansen, CEO
Please read the full press release in English:
Please read the translated press release in Swedish: